menu
    • menu

    Company profile for CARsgen Therapeutics

    NEW Drugs in Dev: 14
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several Fi...
    CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CARsgen TherapeuticsChina Flag
    Country
    Country
    China
    Address
    Address
    1F, Building 2, NO.466 Yindu Road. Xuhui District,Shanghai.
    Telephone
    Telephone
    86-21-64501828
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.carsgen.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/carsgen-therapeutics
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CARsgen, Dispatch Bio Collaborate On Flare Platform, Zevor-Cel
    CARsgen, Dispatch Bio Collaborate On Flare Platform, Zevor-Cel

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/carsgen-and-dispatch-bio-announce-clinical-collaboration-to-evaluate-flare-platform-and-zevor-cel-in-solid-tumors-302658143.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    CARsgen Submits Dual IND Applications for Product CT0596
    CARsgen Submits Dual IND Applications for Product CT0596

    29 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/carsgen-submits-dual-ind-applications-for-allogeneic-bcma-car-t-product-ct0596-302649429.html

    PR NEWSWIRE
    29 Dec 2025
    Share Share
    CARsgen Unveils Allogeneic BCMA CAR-T Data For Multiple Myeloma
    CARsgen Unveils Allogeneic BCMA CAR-T Data For Multiple Myeloma

    08 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/carsgen-announces-data-of-allogeneic-bcma-car-t-cell-therapy-ct0596-for-relapsedrefractory-multiple-myeloma-at-the-2025-ash-annual-meeting-302634742.html

    PR NEWSWIRE
    08 Dec 2025
    Share Share
    CARsgen Zevor-Cel Added to China Commercial Insurance List
    CARsgen Zevor-Cel Added to China Commercial Insurance List

    07 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/carsgens-car-t-product-zevor-cel-included-in-chinas-commercial-health-insurance-innovative-drug-catalogue-302634748.html

    PR NEWSWIRE
    07 Dec 2025
    Share Share
    Carsgen Reveals Favorable Clinical Results For Allogeneic CAR-T
    Carsgen Reveals Favorable Clinical Results For Allogeneic CAR-T

    03 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/carsgen-announces-positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b-302602382.html

    PR NEWSWIRE
    03 Nov 2025
    Share Share
    CARsgen Unveils Satri-Cel Data For Adjuvant Pancreatic Cancer
    CARsgen Unveils Satri-Cel Data For Adjuvant Pancreatic Cancer

    20 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/carsgen-presents-preliminary-results-on-satri-cel-for-adjuvant-therapy-of-pancreatic-cancer-at-esmo-congress-2025-302587311.html

    PR NEWSWIRE
    20 Oct 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search